Biotechnology

Is Dasatinib Dead? – An Incredible Change to the Plausibility Threshold

  It is just over four years since Board 3.3.01 of the EPO Boards of Appeal delivered its much-anticipated decision in the Dasatinib case (T 488/16). Having been closely involved in that case on behalf of one of the opponents, it was obvious to me that the decision represented a...

Read more

Neurodegenerative Disease: Is Your IP Strategy Setting You Up for Success?

With an ever-aging population, one of the biggest challenges facing the modern world is the rising prevalence of neurodegenerative disease. Neurodegenerative disease is a collective term for a number of diseases characterised by the loss of structure, or function, of neurons; the building blocks of the nervous system. Examples of...

Read more

Wisdom of the crowd: how to make sure IP doesn’t derail your crowdfunding efforts

Startups raising hundreds of thousands – even millions – of pounds via Kickstarter may be rarer than it once was, but crowdfunding remains a popular method of fundraising. There are a myriad of options, whether you go down the equity crowdfunding route offered by the likes of Seedrs, CrowdCube, and...

Read more

Petri Dish of the Day: Appetite Increases for Lab-grown Meat Patents

This article was co-authored by Olly Beswestherick “Fifty years hence, we shall escape the absurdity of growing a whole chicken in order to eat the breast or wing by growing these parts separately under a suitable medium.” —Winston Churchill, 1931 Worldwide meat consumption is projected to soar to 73% by...

Read more

Advances in Gene Therapy: The End of the Era of Incurable Genetic Diseases?

Editing an individual’s DNA, to prevent or treat a genetic disease, at one time seemed an impossible task. Remarkably, we are now living in an age of medical development where decades of laboratory research have been successfully translated into gene therapies suitable for human use. Gene therapy may, for example,...

Read more